MannKind Corporation

NasdaqGM MNKD

MannKind Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 8.07%

MannKind Corporation Net Income Margin is 8.07% for the Trailing 12 Months (TTM) ending September 30, 2024, a 133.30% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

MannKind Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -24.24%, a 82.88% change year over year.
MannKind Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -141.57%, a -45.31% change year over year.
MannKind Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -97.43%, a -35.46% change year over year.
MannKind Corporation Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -71.92%, a 4.27% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: MNKD

MannKind Corporation

CEO	Dr. Michael E. Castagna Pharm.D.
IPO Date	July 28, 2004
Location	United States
Headquarters	30930 Russell Ranch Road
Employees	411
Sector	Health Care
Industries Pharmaceuticals Biotechnology Consumer Packaged Goods

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Key trends

Past 5 years